logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
delete
arrow
返回
M

Marina Chiara Garassino

University of Chicago Medicine

73H指数
918论文数
4.4W被引数
收录论文 177
发表时间
logo
Racial Disparities in Thymic Epithelial Tumors: Insights from a Multiracial Urban Cohort胸腺上皮肿瘤中的种族差异：来自多民族城市队列的见解
errClinical Lung Cancer
IF3.3
err2026-09-20
err0
PREAI
errErica Pietroluongo; Christine M. Bestvina; Anna Di Lello; Alessandra Esposito; Maha T Elsebaie; Rachel Brettin; Sulin Wu; Valter Torri; Marina Chiara Garassino
err分享
err收藏
Leave No Data Behind: Exploring a new paradigm in oncology with foundation models and large language models不留数据：探索基于基础模型和大型语言模型的肿瘤学新范式
errCell Reports Medicine
IF10.6
err2026-08-04
err0
errOAAI
errFederica Corso; Aleksandra Zec; Margherita Favali; Marta Ligero; Lars Hilgers; Luca Mauro Invernizzi; Laura Mazzeo; Adria Marcos Morales; Gustav Anton Müller-Franzes; Ines Prata Machado; Felix Busch; Vanja Mišković; Francesco Trovò; Claudia Proto; Giuseppe Lo Russo; Mario Occhipinti; Marta Brambilla; Teresa Beninato; Susan Halabi; Marina Chiara Garassino
err分享
err收藏
ENTRÉE Lung Platform Trial Sub-study 1: Phase II Randomized Efficacy and Safety Analysis of Feladilimab Plus Docetaxel Versus Docetaxel Monotherapy in Advanced/Recurrent NSCLCENTRÉE 肺平台试验子研究1：法拉地利姆单抗联合多西他赛对比多西他赛单药治疗晚期/复发性NSCLC的II期随机疗效与安全性分析
errClinical Lung Cancer
IF3.3
err2026-04-08
err0
PREAI
errMarina Chiara Garassino; Sophie Cousin; Benjamin Besse; Adrian Sacher; Sergey Orlov; Michael Schenker; Enriqueta Felip; Oleg Gladkov; Cristina H. Messina; Antara Majumdar; Zhenhua Jeremy Wu; Natalie O. Karpinich; Steven Hirschfeld; Marc Ballas; Martin Reck
err分享
err收藏
Network analysis predicts pembrolizumab response in advanced NSCLC with PD-L1 < 50%网络分析预测PD-L1<50%的晚期NSCLC对pembrolizumab的应答
errCancer Cell International
IF6
err2026-03-26
err0
errOAAI
errMario Occhipinti; Antonella Cruoglio; Silvia Marchesi; Arsela Prelaj; Marco Petrilli; Aurelia Rughetti; Paolo Ambrosini; Elisabetta Ferretti; Claudia Proto; Monica Ganzinelli; Marta Brambilla; Laura Mazzeo; Teresa Beninato; Filippo de Braud; Marina Chiara Garassino; Lorenzo Farina; Giuseppe Lo Russo; Manuela Petti
err分享
err收藏
Probing Cellular Activity Via Charge-Sensitive Quantum Nanoprobes通过电荷敏感的量子纳米探针探测细胞活性
errAdvanced Materials
IF26.8
err2026-02-04
err0
errOAAI
errUri Zvi; Shivam Mundhra; David Ovetsky; Qing Chen; Aidan R. Jones; Stella Wang; Maria J. Román-Vazquez; Marie Kim; Udoka M. Ibeh; Michele Ferro; Kunle Odunsi; Marina C. Garassino; Michael E. Flatté; Melody A. Swartz; Denis R. Candido; Aaron Esser-Kahn; Peter C. Maurer
err分享
err收藏
Deep Learning Discriminates Thymic Epithelial Tumors Histological Subtypes Using Digital Pathology深度学习利用数字病理学区分胸腺上皮肿瘤的组织学亚型
errAnnals of Oncology
IF65.4
err2025-12-11
err0
PREAI
errMatteo Sacco; Erica Pietroluongo; Anna Di Lello; Mirella Marino; Alexander McGeough; Alessandra Esposito; Rishi Sharma; Aliya N. Husain; Qudsia Arif; Maha A.T. Elsebaie; Alexander T. Pearson; James M. Dolezal; Marina Chiara Garassino
err分享
err收藏
Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed individual patient data meta-analysis晚期非小细胞肺癌患者接受双重CTLA-4和PD-L1或PD-1阻断治疗及生物标志物基础亚组分析的长期总生存：一项系统评价和重建个体患者数据荟萃分析
errThe Lancet Oncology
IF0
err2025-09-29
err0
PREAI
errAlessandro Di Federico; Sara Stumpo; Francesco Mantuano; Andrea De Giglio; Francesca Lo Bianco; Federica Pecci; Joao V Alessi; Xinan Wang; Francesca Sperandi; Barbara Melotti; Francesco Gelsomino; Ferdinandos Skoulidis; Marina C Garassino; Solange Peters; Mark M Awad; Andrea Ardizzoni; Biagio Ricciuti
err分享
err收藏
First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAFV600E-mutated metastatic non-small-cell lung cancer (FRONT-BRAF): a multicentre, retrospective cohort study一线免疫治疗联合或不联合化疗与BRAF联合MEK抑制剂在BRAFV600E突变型转移性非小细胞肺癌中的比较（FRONT-BRAF）：一项多中心、回顾性队列研究
errThe Lancet Oncology
IF0
err2025-09-29
err0
PREAI
errAlessandro Di Federico; Kaiwen Wang; Monica F Chen; Adam A Barsouk; Arianna Pagliaro; Lanyi N Chen; Francesca R Ogliari; Paul Stockhammer; Rajat Thawani; Shahm Raslan; Eleonora Gariazzo; Francesca Fusco; Grace M Hambelton; Fabrizio Citarella; David Meyer; Mihaela Aldea; Andrea De Giglio; Joao V Alessi; Federica Pecci; Francesco Gelsomino; Marcelo Corassa; Natalie I Vokes; Xinan Wang; Dario de Biase; Fawzi Abu Rous; Phurin Areesawangkit; Omar Elghawy; Alessio Cortellini; Giulio Metro; Roberto Ferrara; Mark M Awad; Aliyah Pabani; Joseph C Murray; Federico Cappuzzo; Marina C Garassino; Ibiayi Dagogo-Jack; Gregory Riely; Michael Grant; Benjamin O Herzberg; Andrea Ardizzoni; David Planchard; Bruce E Johnson; Corey J Langer; Michael Offin; Marcelo V Negrao; Biagio Ricciuti
err分享
err收藏
Durvalumab plus platinum-etoposide in extensive-stage small-cell lung cancer: outcomes in age, sex, and platinum subgroups from the phase 3 CASPIAN study度伐利尤单抗联合铂类-依托泊苷治疗广泛期小细胞肺癌：CASPIAN III期研究中不同年龄、性别和铂类亚组的结果
errClinical Lung Cancer
IF3.3
err2025-08-05
err0
errOAAI
errNiels Reinmuth; Jonathan W. Goldman; Yuanbin Chen; Katsuyuki Hotta; Dmytro Trukhin; Galina Statsenko; Maximilian Hochmair; Mustafa Özgüroğlu; Jun Ho Ji; Marina Chiara Garassino; Artem Poltoratskiy; Francesco Verderame; Libor Havel; Igor Bondarenko; György Losonczy; Nikolay Conev; Shannon Kummer; Helen Mann; Priti Chugh; Tapashi Dalvi; Luis Paz-Ares
err分享
err收藏
THE ITALIAN MAURIS PHASE IIIB TRIAL OF ATEZOLIZUMAB PLUS CARBOPLATIN AND ETOPOSIDE FOR PATIENTS WITH NEWLY DIAGNOSED EXTENSIVE-STAGE SMALL CELL LUNG CANCER: 3-YEAR END-OF-STUDY RESULTS意大利MAURIS 3期B研究：阿替利珠单抗联合卡铂和依托泊苷治疗新诊断广泛期小细胞肺癌的3年研究结束结果
errClinical Lung Cancer
IF3.3
err2025-07-09
err0
errOAAI
errFloriana Morgillo; Ester Del Signore; Emilio Bria; Filippo de Marinis; Fortunato Ciardiello; Marina Chiara Garassino; Alessio Stefani; Francesco Verderame; Alessandro Morabito; Andrea Sbrana; Giuseppe Tonini; Marina Gilli; Rossana Berardi; Paola Adriana Taveggia; Alessandra Bearz; Angelo Delmonte; Maria Rita Migliorino; Cesare Gridelli; Giovanni Maria Fadda; Manuela Iero; Andrea Ardizzoni
err分享
err收藏
Impact of Tumor Response and Response Duration on Survival Among Participants Receiving Pembrolizumab Plus Chemotherapy as First-Line Therapy for Non-Small-Cell Lung Cancer接受帕博利珠单抗联合化疗作为非小细胞肺癌一线治疗的患者中，肿瘤应答和应答持续时间对生存的影响
errOncology and Therapy
IF3.2
err2025-06-11
err0
errOAAI
errMarina C. Garassino; Ying Cheng; Delvys Rodriguez-Abreu; Silvia Novello; Julien Mazieres; Andrew G. Robinson; Steven F. Powell; Balazs Halmos; Jhanelle E. Gray; Meihua Wang; Cong Chen; Jing Yang; Fabricio Souza; Paul Schwarzenberger; Luis Paz-Ares
err分享
err收藏
Durvalumab after sequential chemoradiotherapy in unresectable stage III non-small-cell lung cancer—final analysis from the phase II PACIFIC-6 trial度伐利尤单抗在不可切除的III期非小细胞肺癌患者序贯化放疗后的应用——来自PACIFIC-6 II期试验的最终分析
errESMO Open
IF8.3
err2025-06-01
err0
errOAAI
errM.C. Garassino; J. Khalifa; M. Reck; C. Chouaid; H. Bischoff; N. Reinmuth; L. Cove-Smith; T. Mansy; D.L. Cortinovis; M.R. Migliorino; A. Delmonte; J. Garcia Sánchez; L.E. Chara Velarde; R. Bernabe; L. Paz-Ares; P. Chander; I. Diaz Perez; K. Foroutanpour; U. Emeribe; C. Faivre-Finn
err分享
err收藏
Neoadjuvant vs perioperative chemo-immunotherapy according to pathological response in resectable non-small cell lung cancer: a reconstructed individual patient data meta-analysis新辅助与围手术期化免疫疗法根据病理反应在可切除非小细胞肺癌中的比较：一项重构的个体患者数据meta分析
errJNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
IF7.2
err2025-06-01
err1
PREAI
errNuccio, Antonio; Salomone, Fabio; Servetto, Alberto; Ricciuti, Biagio; Marinelli, Daniele; Bulotta, Alessandra; Veronesi, Giulia; Garassino, Marina Chiara; Torri, Valter; Besse, Benjamin; Viscardi, Giuseppe; Ferrara, Roberto
err分享
err收藏
Adverse events self-reported by patients with extensive-stage small-cell lung cancer in the phase III CASPIAN study在CASPIAN III期研究中，广泛期小细胞肺癌患者自报的不良事件
errFUTURE ONCOLOGY
IF2.6
err2025-05-07
err0
errOAAI
errOzguroglu, Mustafa; Goldman, Jonathan W.; Chen, Yuanbin; Garassino, Marina Chiara; Medic, Nenad; Mann, Helen; Chugh, Priti; Dalvi, Tapashi; Paz-Ares, Luis
err分享
err收藏
Cemiplimab Monotherapy for First-Line Treatment of Patients with Advanced NSCLC With PD-L1 Expression of 50% or Higher: Five-Year Outcomes of EMPOWER-Lung 1Cemiplimab单药治疗PD-L1表达≥50%的晚期NSCLC患者的一线治疗：EMPOWER-Lung 1研究五年结局
errJournal of Thoracic Oncology
IF20.8
err2025-03-19
err0
errOAAI
errSaadettin Kilickap; Ana Baramidze; Ahmet Sezer; Mustafa Özgüroğlu; Mahmut Gumus; Igor Bondarenko; Miranda Gogishvili; Marina Nechaeva; Michael Schenker; Irfan Cicin; Ho Gwo Fuang; Yaroslav Kulyaba; Kasimova Zyuhal; Roxana-Ioana Scheusan; Marina Chiara Garassino; Yuntong Li; Cong Zhu; Manika Kaul; Javier Perez; Frank Seebach; Heather Magnan
err分享
err收藏
Non-small-cell lung cancer (vol 10, 71, 2024)非小细胞肺癌（vol 10, 71, 2024）
errNATURE REVIEWS DISEASE PRIMERS
IF60.6
err2025-01-07
err0
PREAI
errHendriks, Lizza E. L.; Remon, Jordi; Faivre-Finn, Corinne; Garassino, Marina C.; Heymach, John V.; Kerr, Keith M.; Tan, Daniel S. W.; Veronesi, Giulia
err分享
err收藏
Non-small-cell lung cancer非小细胞肺癌
errNATURE REVIEWS DISEASE PRIMERS
IF60.6
err2024-09-26
err0
PREAI
errHendriks, Lizza E. L.; Remon, Jordi; Faivre-Finn, Corinne; Garassino, Marina C.; Heymach, John V.; Kerr, Keith M.; Tan, Daniel S. W.; Veronesi, Giulia; Reck, Martin
err分享
err收藏
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial在早期非小细胞肺癌患者中，新辅助派姆单抗加化疗后辅助派姆单抗与单独新辅助化疗的比较 (KEYNOTE-671): 一项随机，双盲，安慰剂对照的3期试验
errLANCET
IF88.5
err2024-09-01
err4
PREAI
errSpicer, Jonathan D.; Garassino, Marina C.; Wakelee, Heather; Liberman, Moishe; Kato, Terufumi; Tsuboi, Masahiro; Lee, Se-Hoon; Chen, Ke-Neng; Dooms, Christophe; Majem, Margarita; Eigendorff, Ekkehard; Martinengo, Gaston L.; Bylicki, Olivier; Rodriguez-Abreu, Delvys; Chaft, Jamie E.; Novello, Silvia; Yang, Jing; Arunachalam, Ashwini; Keller, Steven M.; Samkari, Ayman; Gao, Shugeng
err分享
err收藏
Top 20 EGFR+ NSCLC Clinical and Translational Science Papers That Shaped the 20 Years Since the Discovery of Activating EGFR Mutations in NSCLC. An Editor-in-Chief Expert Panel Consensus Survey.前20名EGFR NSCLC临床和转化科学论文，塑造了NSCLC中激活EGFR突变发现的20年。主编专家小组共识调查。
errLUNG CANCER-TARGETS AND THERAPY
IF3.3
err2024-06-01
err0
errOAAI
errOu, Sai-Hong Ignatius; Le, Xiuning; Nagasaka, Misako; Reungwetwattana, Thanyanan; Ahn, Myung-Ju; Lim, Darren W. T.; Santos, Edgardo S.; Shum, Elaine; Lau, Sally C. M.; Lee, Jii Bum; Calles, Antonio; Wu, Fengying; Lopes, Gilberto; Sriuranpong, Virote; Tanioki, Junko; Horinouchi, Hidehito; Garassino, Marina C.; Popat, Sanjay; Besse, Benjamin; Rosell, Rafael; Soo, Ross A.
err分享
err收藏
Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 study
errMOLECULAR CANCER
IF33.9
err2024-05-30
err4
errOAAI
errXie, Mingchao; Vuko, Miljenka; Rodriguez-Canales, Jaime; Zimmermann, Johannes; Schick, Markus; O'Brien, Cathy; Paz-Ares, Luis; Goldman, Jonathan W.; Garassino, Marina Chiara; Gay, Carl M.; Heymach, John V.; Jiang, Haiyi; Barrett, J. Carl; Stewart, Ross A.; Lai, Zhongwu; Byers, Lauren A.; Rudin, Charles M.; Shrestha, Yashaswi
err分享
err收藏

研究方向

暂时未获取到该数据
合作学者
合作期刊
C
Carlo M. Croce
H 指数: 209 · 论文数: 1.8K
P
Pasi A. Jänne
H 指数: 163 · 论文数: 2.3K
F
Funda Meric‐Bernstam
H 指数: 146 · 论文数: 2.6K
J
J. Jack Lee
H 指数: 146 · 论文数: 2.8K
J
Josep Tabernero
H 指数: 146 · 论文数: 2.7K
查看更多